Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
37.56%
Operating Margin
14.45%
Net Margin
10.22%
Efficiency Metrics
Revenue per Expense Ratio
1.17
R&D as % of Revenue
1.42%
Earnings Quality
EBITDA Margin
18.11%
Income Tax Rate
21.85%
EPS
2.5400000000
Balance Sheet Analysis
Current Ratio
0.65
Cash Ratio
0.05
Working Capital
$-1.10B
Debt to Equity
0.91
Debt to Assets
35.70%
Equity Ratio
39.35%
Cash Flow Analysis
Operating Cash Flow Ratio
18.57%
Free Cash Flow Ratio
14.61%
CapEx to Revenue
3.96%
Dividends Paid
$418.50M
Stock Buybacks
$35.70M
Total Shareholder Returns
$454.20M
Cash Position Change
-50.12%
Key Takeaways (2023 FY)
Increased dividend payments by 5.42%
Increased R&D investment by 8.46%
Detailed Growth Metrics
Core Performance
Revenue
4.91%
Net Income
-0.21%
EPS
0.00%
Operating Income
11.51%
Operational Efficiency
R&D Expenses
8.46%
SG&A Expenses
1.94%
Operating Cash Flow
89.92%
Free Cash Flow
149.91%
Balance Sheet Health
Assets
-2.00%
Debt
-13.79%
Book Value per Share
8.10%
Inventory
-15.94%
Shareholder Returns
Dividends per Share
5.42%
Shares Outstanding
0.07%
Long Term Trends
3Y Revenue/Share
18.10%
5Y Revenue/Share
23.15%
3Y Dividend/Share
25.88%
5Y Dividend/Share
50.05%